Literature DB >> 12625796

Treating generalized anxiety disorder.

Jack M Gorman1.   

Abstract

Generalized anxiety disorder (GAD) is characterized by chronically persistent worry and therefore requires effective long-term treatment. This article reviews the benefits and risks associated with various pharmacologic and psychological therapies to assess their ability to achieve the elimination of GAD symptomatology and restoration of normal function. Psychotherapeutic approaches such as applied relaxation, cognitive therapy, and cognitive-behavioral therapy have all been shown to be effective when used as monotherapies and may be beneficial when used adjunctively. Current effective pharmacotherapies for patients with GAD include anxiolytic benzodiazepines, buspirone, and antidepressants including venlafaxine and paroxetine. Benzodiazepines have long been used to treat anxiety and are particularly appropriate in short-term treatment situations; however, their adverse side-effect profile and their inability to treat depression commonly comorbid with GAD renders them less than ideal in many situations. Buspirone has demonstrated anxiolytic benefits but, like benzodiazepines, shows negligible antidepressant action. Antidepressants like paroxetine and venlafaxine are not only effective antidepressants but also effective anxiolytics, thus implying their special ability to treat GAD and concurrent depression, even over the long-term.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12625796

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

1.  Effects of milnacipran in animal models of anxiety and memory.

Authors:  Vânia K M Moojen; Márcio Rodrigo Martins; Adalisa Reinke; Gustavo Feier; Fabiano R Agostinho; Edson M Cechin; João Quevedo
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

2.  Two inbred rat strains contrasting for anxiety-related behaviors show similar levels of defensive responses to cat odor.

Authors:  Gustavo R Brüske; Leandro F Vendruscolo; André Ramos
Journal:  Behav Brain Funct       Date:  2007-04-13       Impact factor: 3.759

3.  Collaborative stepped care for anxiety disorders in primary care: aims and design of a randomized controlled trial.

Authors:  Anna D T Muntingh; Christina M van der Feltz-Cornelis; Harm W J van Marwijk; Philip Spinhoven; Willem J J Assendelft; Margot W M de Waal; Leona Hakkaart-van Roijen; Herman J Adèr; Anton J L M van Balkom
Journal:  BMC Health Serv Res       Date:  2009-09-08       Impact factor: 2.655

4.  Duloxetine in the treatment of generalized anxiety disorder.

Authors:  Alan Wright; Chad Vandenberg
Journal:  Int J Gen Med       Date:  2009-12-29

5.  Attention modification program in individuals with generalized anxiety disorder.

Authors:  Nader Amir; Courtney Beard; Michelle Burns; Jessica Bomyea
Journal:  J Abnorm Psychol       Date:  2009-02

Review 6.  Contemporary assessment and pharmacotherapy of Tourette syndrome.

Authors:  Lawrence Scahill; Gerald Erenberg; Cheston M Berlin; Cathy Budman; Barbara J Coffey; Joseph Jankovic; Louise Kiessling; Robert A King; Roger Kurlan; Anthony Lang; Jonathan Mink; Tanya Murphy; Samual Zinner; John Walkup
Journal:  NeuroRx       Date:  2006-04

7.  Cellular correlates of enhanced anxiety caused by acute treatment with the selective serotonin reuptake inhibitor fluoxetine in rats.

Authors:  Shilpa Ravinder; Anup G Pillai; Sumantra Chattarji
Journal:  Front Behav Neurosci       Date:  2011-12-28       Impact factor: 3.558

8.  Magnitude of potentially inappropriate prescribing in Germany among older patients with generalized anxiety disorder.

Authors:  Ariel Berger; Marko Mychaskiw; Ellen Dukes; John Edelsberg; Gerry Oster
Journal:  BMC Geriatr       Date:  2009-07-27       Impact factor: 3.921

9.  A role for the extended amygdala in the fear-enhancing effects of acute selective serotonin reuptake inhibitor treatment.

Authors:  S Ravinder; N S Burghardt; R Brodsky; E P Bauer; S Chattarji
Journal:  Transl Psychiatry       Date:  2013-01-15       Impact factor: 6.222

10.  Change in healthcare utilization and costs following initiation of benzodiazepine therapy for long-term treatment of generalized anxiety disorder: a retrospective cohort study.

Authors:  Ariel Berger; John Edelsberg; Michael Treglia; Jose Ma J Alvir; Gerry Oster
Journal:  BMC Psychiatry       Date:  2012-10-23       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.